Anifrolumab-fnia - Biologic Drug Details

Summary for anifrolumab-fnia

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for anifrolumab-fnia

Mechanism of Action	Type I Interferon Receptor Antagonists
Established Pharmacologic Class	Type I Interferon Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for anifrolumab-fnia Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for anifrolumab-fnia Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for anifrolumab-fnia Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Anifrolumab-fnia

Last updated: February 19, 2026

What is the commercial status of anifrolumab-fnia?

Anifrolumab-fnia is a biologic monoclonal antibody developed by AstraZeneca targeting the type I interferon receptor, primarily indicated for systemic lupus erythematosus (SLE). The drug was approved by the U.S. Food and Drug Administration (FDA) in August 2021 under the brand name Saphnelo. Its European approval followed in September 2022.

How does the pharmaceutical landscape look for anifrolumab-fnia?

The SLE therapeutics market primarily comprises immunosuppressants, corticosteroids, and biologics. Key players include GlaxoSmithKline (Benlysta), AstraZeneca (Saphnelo), and newer entrants like Eli Lilly. The lupus biologics segment is competitive but remains relatively limited with only a handful of approved options.

Market size in 2022 was approximately $1.2 billion globally. Diagnosis and treatment rates have increased due to better awareness and earlier diagnosis, contributing to growth potential.

Year	Global Market Size (USD billion)	CAGR (2022-2028)	Key Drivers
2022	1.2	9.5%	Growing prevalence of SLE, approval of new biologics, unmet needs
2023	1.32		Increased prescription volume, expanded indications
2028	2.2		Greater market penetration, competitive pricing, off-label use growth

What are the factors influencing the financial trajectory?

1. Market Penetration and Adoption

Anifrolumab-fnia's approval in multiple major markets (U.S., EU) positions it as a significant option for SLE treatment. Prescribed mainly for adult patients with moderate to severe disease, it targets an unmet medical need.

Initial sales are constrained by factors such as competitive treatment algorithms, licensing restrictions, and physician familiarity. The drug’s current market share is estimated at 10-15% within the SLE biologics segment.

2. Pricing Strategies and Reimbursement

In the U.S., the wholesale acquisition cost (WAC) is approximately $42,000 per year per patient. Insurance reimbursement varies, with payer coverage improving as real-world evidence accumulates and clinical benefits are demonstrated.

European pricing is typically lower, averaging €30,000-€35,000 annually, influenced by health authority negotiations and regional affordability measures.

3. Clinical Efficacy and Safety Profile

Anifrolumab-fnia demonstrates a reduction in disease severity and flares, with a favorable safety profile. The Phase III TULIP trials showed a 47% response rate in the primary endpoint, compared to 31% in placebo (Furie et al., 2019). Its efficacy supports broader adoption, pending evidence of long-term benefit and safety.

4. Regulatory and Patent Landscape

Expanding indications and approvals are key to revenue growth. Patent protection extends into the late 2030s, providing a period of market exclusivity. However, biosimilar competition is anticipated post-patent expiry, especially from established biologics like Benlysta.

5. Market Expansion Opportunities

Off-label uses and combination therapies could increase sales. Market expansion into other autoimmune diseases such as dermatomyositis or cutaneous lupus remains unvalidated but under investigation.

What are the near-term growth prospects?

Expected annual sales growth is projected at 10-12% through 2028. Launch of biosimilar competitors and increased clinician awareness are factors to monitor. The drug's market share could reach 20-25% within the next five years, assuming steady clinical adoption and reimbursement policies.

What risks could impact the financial trajectory?

• Regulatory delays or restrictions
• Competition from existing or upcoming therapies
• Pricing pressures and reimbursement limits
• Off-label use restrictions
• Long-term safety concerns emerging post-market

Key Takeaways

• Anifrolumab-fnia is a leading biologic for SLE, approved in major markets since 2021.
• The global market is expanding due to rising disease prevalence, with an estimated CAGR of approximately 9.5% through 2028.
• Revenue growth depends on market penetration, pricing, reimbursement, and clinical data.
• Competitive threats include biosimilar entrants and new therapeutic candidates.
• Long-term financial success relies on gaining broader indications and continuous clinical validation.

FAQs

1. What is the primary mechanism of action of anifrolumab-fnia?
It blocks the type I interferon receptor, reducing immune response related to SLE.

2. When is the expected patent expiry for anifrolumab-fnia?
Patent protection extends until approximately 2038, providing market exclusivity during this period.

3. How does anifrolumab-fnia compare to Benlysta?
Anifrolumab-fnia targets the interferon receptor, while Benlysta inhibits B-lymphocyte stimulator (BLyS). Efficacy and safety profiles are comparable, but clinical preferences vary.

4. What are the main barriers to increased adoption?
High treatment costs, physician familiarity, and insurance coverage issues.

5. What potential markets could exhibit growth beyond SLE?
Autoimmune diseases such as dermatomyositis and cutaneous lupus are under clinical investigation as off-label options.

---

References

[1] Furie, R., et al. (2019). Anifrolumab in active systemic lupus erythematosus. New England Journal of Medicine, 382(3), 221-232.
[2] MarketResearch.com. (2023). Global Lupus Biologics Market Report.
[3] AstraZeneca. (2021). Saphnelo (anifrolumab-fnia) prescribing information.
[4] European Medicines Agency. (2022). Saphnelo approval summary.